(Translation of registrant’s name into English)

 

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒

Form 40-F ☐

 

 

Exhibit Number	Description
99.1	2 April 2024 - “Total Voting Rights and Capital”

 

 

 

 

99.1

 

 

 

 

 

2 April 2024: As at 31 March 2024 the total number of shares issued by Haleon plc ("Haleon" or the "Company") with rights to vote is 9,132,301,104 ordinary shares of £0.01 each. There are no ordinary shares held in Treasury.

 

The figure of 9,132,301,104 may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Notifiable interests in Haleon may be sent to: company.secretary@haleon.com

 

 

 

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com. 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

		HALEON PLC (Registrant)
Date: April 2, 2024	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary